Business
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for pharmaceutical research and development. Under the partnership, Lunit's AI pathology solutions will be offered as part of CellCarta's services for global clinical trials, making it easier for pharma sponsors to adopt AI-powered analysis within existing trial workflows.
About this update from Lunit Inc.
[{"type":"text","content":"SEOUL, South Korea and MONTREAL, Sept. 24, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for pharmaceutical research and development. Under the partnership, Lunit's AI pathology solutions will be offered as part of CellCarta's services for global clinical trials, making it easier for pharma sponsors to adopt AI-powered analysis within existing trial workflows.","length":572,"tagName":"p"},{"type":"image","alt":"Lunit and CellCarta join forces to bring AI-powered pathology into worldwide clinical trial workflows.","displaySize":"","headline":null,"caption":"Lunit and CellCarta join forces to bring AI-powered pathology into worldwide clinical trial workflows.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":221,"url":"https://media.zenfs.com/en/prnewswire.com/2d66cebae566f292d5d1d82c7c05cf43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Tce2Yz_LfpvG7Y6PN9l7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2d66cebae566f292d5d1d82c7c05cf43","width":400,"height":221}},"href":"https://mma.prnewswire.com/media/2780796/Lunit_CellCarta_join_forces_bring_AI_powered_pathology_worldwide_clinical_trial.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"CellCarta operates CAP-accredited/CLIA-certified laboratories across North America, Europe, and Asia, and is widely recognized for its expertise in pathology, biomarker development, and global clinical trial support across oncology and immunology. The company has participated in more than 1,000 clinical studies—including 75 Phase III PMA trials—developed over 250 unique IHC assays, and performs more than 100,000 IHC stainings annually.","length":439,"tagName":"p"},{"type":"text","content":"The collaboration aims to broaden access to the Lunit SCOPE® suite, Lunit's digital pathology AI solution, and deliver faster, more scalable insights into tumor biology through the analysis of H&E and IHC whole slide images. These insights help identify patients likely to benefit from specific therapies, support biomarker development, and ultimately advance precision oncology and drug de...